Literature DB >> 26874174

Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report.

Alfred Basilious1, John C Lloyd2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26874174     DOI： 10.1016/j.jcjo.2015.09.008

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN： 0008-4182            Impact factor:   1.882


× No keyword cloud information.
  15 in total

1.  Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.

Authors:  Michel M Sun; Ralph D Levinson; Artur Filipowicz; Stephen Anesi; Henry J Kaplan; Wei Wang; Debra A Goldstein; Sapna Gangaputra; Robert T Swan; H Nida Sen; Lynn K Gordon
Journal:  Ocul Immunol Inflamm       Date:  2019-03-01       Impact factor: 3.070

Review 2.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

Review 3.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

Review 4.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

5.  Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis.

Authors:  Mike Nguyen; Md Rafiqul Islam; Shueh Wen Lim; Arvind Sahu; Babak Tamjid
Journal:  Front Oncol       Date:  2019-09-23       Impact factor: 6.244

6.  Bilateral uveitis and macular edema induced by Nivolumab: a case report.

Authors:  Claire Theillac; Morgane Straub; Anne-Laure Breton; Luc Thomas; Stéphane Dalle
Journal:  BMC Ophthalmol       Date:  2017-12-01       Impact factor: 2.209

7.  Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis.

Authors:  John A Gonzales; Jessica Shantha; Nisha R Acharya
Journal:  Am J Ophthalmol Case Rep       Date:  2018-02-08

8.  Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Meifen Zhang; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-04       Impact factor: 3.500

Review 9.  [Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy].

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Juhong Shi; Meifen Zhang; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.